Defining the Values and Quality of Life of Cancer Survivors Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An International Survey Study.
HIPEC
Patient-reported outcomes
Pertioneal malignancy
Value-based healthcare
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
23
05
2023
accepted:
11
07
2023
medline:
12
10
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
Advances in treatment of peritoneal surface malignancies including cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS±HIPEC) have led to long-term survivorship, yet the subsequent quality of life (QOL) and values of these patients are unknown. Survivors were offered surveys via online support groups. Novel items assessed how patients prioritized experience, costs, longevity, and wellbeing. Of the 453 gastrointestinal/hepatobiliary (GI/HPB) surgical patients that responded, 74 underwent CRS±HIPEC and were 54±12 years old, 87% female, and 93% white. Respondents averaged 29 months from diagnosis, with a maximum survival of 20 years. With a moderate level of agreement (W = 39%), rankings of value metrics among respondents were predictable (p < 0.001). Longevity and functional independence were ranked highest; treatment experience and cost of treatment were ranked lowest (p < 0.001). Those who underwent CRS±HIPEC or other GI/HPB surgeries reported the same rank order. QOL in CRS±HIPEC survivors, both mental (M-QOL) (44±13) and physical (P-QOL) (41±11) were lower than in the general population (50±10); p < 0.001. Impairments persisted throughout survivorship, but M-QOL improved over time (p < 0.05). When comparing CRS±HIPEC with other GI/HPB cancer surgery survivors, M-QOL (43±13 versus 43±14, p = 0.85) and P-QOL (40±11 versus 42±12, p = 0.41) were similar. Although CRS±HIPEC survivors experience long-term mental and physical health impairments, they were similar to those experienced by survivors of other GI/HPB cancer surgeries, and their QOL improved significantly throughout survivorship. As CRS±HIPEC survivors prioritize longevity above all other metrics, survival benefit may outweigh a temporary reduction in QOL.
Sections du résumé
BACKGROUND
BACKGROUND
Advances in treatment of peritoneal surface malignancies including cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS±HIPEC) have led to long-term survivorship, yet the subsequent quality of life (QOL) and values of these patients are unknown.
PATIENTS AND METHODS
METHODS
Survivors were offered surveys via online support groups. Novel items assessed how patients prioritized experience, costs, longevity, and wellbeing.
RESULTS
RESULTS
Of the 453 gastrointestinal/hepatobiliary (GI/HPB) surgical patients that responded, 74 underwent CRS±HIPEC and were 54±12 years old, 87% female, and 93% white. Respondents averaged 29 months from diagnosis, with a maximum survival of 20 years. With a moderate level of agreement (W = 39%), rankings of value metrics among respondents were predictable (p < 0.001). Longevity and functional independence were ranked highest; treatment experience and cost of treatment were ranked lowest (p < 0.001). Those who underwent CRS±HIPEC or other GI/HPB surgeries reported the same rank order. QOL in CRS±HIPEC survivors, both mental (M-QOL) (44±13) and physical (P-QOL) (41±11) were lower than in the general population (50±10); p < 0.001. Impairments persisted throughout survivorship, but M-QOL improved over time (p < 0.05). When comparing CRS±HIPEC with other GI/HPB cancer surgery survivors, M-QOL (43±13 versus 43±14, p = 0.85) and P-QOL (40±11 versus 42±12, p = 0.41) were similar.
CONCLUSIONS
CONCLUSIONS
Although CRS±HIPEC survivors experience long-term mental and physical health impairments, they were similar to those experienced by survivors of other GI/HPB cancer surgeries, and their QOL improved significantly throughout survivorship. As CRS±HIPEC survivors prioritize longevity above all other metrics, survival benefit may outweigh a temporary reduction in QOL.
Identifiants
pubmed: 37535272
doi: 10.1245/s10434-023-14034-w
pii: 10.1245/s10434-023-14034-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7825-7832Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012. https://doi.org/10.1200/JCO.2011.39.7166 .
doi: 10.1200/JCO.2011.39.7166
pubmed: 23182988
Hall B, Padussis J, Foster JM. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastasis. Surg Clin North Am. 2017;97(3):671–82. https://doi.org/10.1016/j.suc.2017.01.013 .
doi: 10.1016/j.suc.2017.01.013
pubmed: 28501254
Zhang J, Li X-B, Ma R, Ji Z-H, Bai W, Li Y. Long term survival of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in advanced epithelial ovarian cancer. Transl Cancer Res. 2021;10(8):3705–15. https://doi.org/10.21037/tcr-20-3233 .
doi: 10.21037/tcr-20-3233
pubmed: 35116671
pmcid: 8798645
Teisberg E, Wallace S, O’Hara S. Defining and implementing value-based health care: a strategic framework. Acad Med. 2020;95(5):682–5. https://doi.org/10.1097/ACM.0000000000003122 .
doi: 10.1097/ACM.0000000000003122
pubmed: 31833857
Larsson S, Clawson J, Howard R. Value-based health care at an inflection point: a global agenda for the next decade. NEJM Catalyst Innovat Care Deliv. 2023. https://doi.org/10.1056/CAT.22.0332 .
doi: 10.1056/CAT.22.0332
Allen CJ, Thaker NG, Prakash L, et al. Communicating value: use of a novel framework in the assessment of an enhanced recovery initiative. Ann Surg. 2021;273(1):e7–9. https://doi.org/10.1097/SLA.0000000000004050 .
doi: 10.1097/SLA.0000000000004050
pubmed: 32568750
Allen CJ, Smith GL, Prakash L, et al. What is “value”? Results of a survey of cancer patients and providers. Ann Surg Oncol. 2022;29(11):6537–45. https://doi.org/10.1245/s10434-022-11534-z .
doi: 10.1245/s10434-022-11534-z
pubmed: 35391609
Halkia E, Kopanakis N, Nikolaou G, Spiliotis J. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality. J BUON. 2015;20.
Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33. https://doi.org/10.1097/00005650-199603000-00003 .
doi: 10.1097/00005650-199603000-00003
pubmed: 8628042
Stewart, AL, Ware JE, Measuring functioning and well-being: the medical outcomes study approach. 1992, Durham: Duke University Press. xxiii, 449 p
Jenkinson C, Layte R. Development and testing of the UK SF-12 (short form health survey). J Health Serv Res Policy. 1997;2(1):14–8. https://doi.org/10.1177/135581969700200105 .
doi: 10.1177/135581969700200105
pubmed: 10180648
Ware JE, Kosinksi M, Keller SD. SF-12: {How} to Score the SF12 Physical & Mental Health Summary Scales, Third Edition. 2nd ed. Boston; 2001.
Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience. J Clin Oncol. 2009. https://doi.org/10.1200/JCO.2009.23.9640 .
doi: 10.1200/JCO.2009.23.9640
pubmed: 20008640
pmcid: 2815707
Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010. https://doi.org/10.1016/j.ejso.2010.01.006 .
doi: 10.1016/j.ejso.2010.01.006
pubmed: 20605396
Tsilimparis N, Bockelmann C, Raue W, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol. 2013. https://doi.org/10.1245/s10434-012-2579-9 .
doi: 10.1245/s10434-012-2579-9
pubmed: 22868919
Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. Eur J Surg Oncol. 2014. https://doi.org/10.1016/j.ejso.2014.08.477 .
doi: 10.1016/j.ejso.2014.08.477
pubmed: 25242382
McQuellon RP, Danhauer SC, Russell GB, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007. https://doi.org/10.1245/s10434-006-9304-5 .
doi: 10.1245/s10434-006-9304-5
pubmed: 18030535
McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001. https://doi.org/10.1053/ejso.2000.1033 .
doi: 10.1053/ejso.2000.1033
pubmed: 11237495
Alexander R, Mavroukakis S, Libutti S, et al. Impact of tumor resection (Rxn) and intraperitoneal (IP) chemotherapy (CHRx) on health related quality of life (HRQL) in patients (Pts) with peritoneal surface malignancies (PSM). Ann Surg Oncol. 2004. https://doi.org/10.1007/bf02524154 .
doi: 10.1007/bf02524154
pubmed: 14993024
Lim SJ, Cormier JN, Feig BW, et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol. 2007. https://doi.org/10.1245/s10434-007-9463-z .
doi: 10.1245/s10434-007-9463-z
pubmed: 18057989
Macrí A, Maugeri I, Trimarchi G, et al. Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitionaeal chemotherapy for peritioneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. In Vivo (Brooklyn). 2009;23(1).
Allen CJ, Johnson FM, In H, Katz MHG, Snyder RA. Shifting the focus: value-based care in surgical oncology. Ann Surg Oncol. 2023;30(7):3871–74. https://doi.org/10.1245/s10434-023-13369-8 .
Oliver A, Greenberg CC. Measuring outcomes in oncology treatment: the importance of patient-centered outcomes. Surg Clin North Am. 2009. https://doi.org/10.1016/j.suc.2008.09.015 .
doi: 10.1016/j.suc.2008.09.015
pubmed: 19186228
pmcid: 4539252
Chua TC, Martin S, Saxena A, et al. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. Ann Surg. 2010;251(2):323–9. https://doi.org/10.1097/SLA.0b013e3181c9b53c .
doi: 10.1097/SLA.0b013e3181c9b53c
pubmed: 20040853
Lee ZJ, Chia SL, Tan G, Soo KC, Teo CCM. Cost effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2018;25(8):2340–6. https://doi.org/10.1245/s10434-018-6508-4 .
doi: 10.1245/s10434-018-6508-4
pubmed: 29948417